Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:businessModel |
research-based
|
| gptkbp:clinicalTrials |
international
ongoing quality of life cancer completed data-driven safety multinational efficacy collaborative kidney diseases evidence-based autoimmune disorders patient-centric phase I phase II phase III |
| gptkbp:collaboratesWith |
academic institutions
|
| gptkbp:communityEngagement |
patient advocacy
public health initiatives health education |
| gptkbp:employees |
approximately 200
|
| gptkbp:focus |
biopharmaceuticals
|
| gptkbp:founded |
2002
|
| gptkbp:globalPresence |
yes
|
| gptkbp:headquarters |
gptkb:London,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chugai Pharma Europe
|
| gptkbp:investmentFocus |
innovation
research development |
| gptkbp:market |
Europe
|
| gptkbp:marketSegment |
value-based care
patient access healthcare_partnerships |
| gptkbp:offers |
therapeutics for autoimmune diseases
therapeutics for oncology therapeutics for renal diseases |
| gptkbp:operatesIn |
Europe
|
| gptkbp:parentCompany |
gptkb:Chugai_Pharmaceutical_Co.,_Ltd.
|
| gptkbp:partnerships |
gptkb:Roche
pharmaceutical companies research institutions biotech companies |
| gptkbp:regulatoryCompliance |
gptkb:European_Medicines_Agency
|
| gptkbp:research_areas |
yes
oncology immunology nephrology |
| gptkbp:researchAndDevelopment |
clinical trials
|
| gptkbp:researchFocus |
targeted therapies
combination therapies novel therapies |
| gptkbp:specializesIn |
innovative medicines
|
| gptkbp:subsidiary |
gptkb:Chugai_Pharmaceutical_Co.,_Ltd.
|
| gptkbp:sustainabilityInitiatives |
governance
social responsibility environmental responsibility |
| gptkbp:teamAchievements |
monoclonal antibodies
biologics small molecules |
| gptkbp:website |
www.chugai-pharma.co.uk
|